Table 1 Baseline patient demographics and characteristics for parts A, B, and C of the CC-90010-ST-001 study

From: BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas

Patient characteristic

Part A (solid tumors) (n = 69)

Part B

Part C (solid tumors) (n = 41)

BCC & NUT carcinomaa (n = 2)

R/R DLBCLb (n = 23)

Age, median, y (range)

57 (21–80)

67 (59–75)

66 (35–79)

58 (20–79)

 ≥65 y, n (%)

21 (30)

1 (50)

12 (52)

11 (27)

Male, n (%)

38 (55)

1 (50)

12 (52)

18 (44)

Female, n (%)

31 (45)

1 (50)

11 (48)

23 (56)

ECOG PS, n (%)

 0

33 (48)

0

7 (30)

26 (63)

 1

36 (52)

2 (100)

16 (70)

15 (37)

Tumor type, n (%)

 Glioblastoma

10 (14)

0

0

2 (5)

 BCC

0

1 (50)

0

0

 NUT carcinoma

0

1 (50)

0

1 (2)

 Other solid tumorc

57 (83)

0

0

38 (93)

 DLBCL

2 (3)

0

23 (100)

0

Prior systemic cancer therapies, median, n (range)

4 (1–9)

1d

4 (2–7)

2 (1–8)

Prior stem cell transplant, n (%)

0

0

6 (26)

0

Time from the initial diagnosis to the first dose of study drug, median, months (range)

40.6 (2.2–506.7)

222.8 (1.1–444.6)

28.5 (5.0–153.5)

35.7 (5.6–268.6)

  1. BCC basal cell carcinoma, DLBCL diffuse large B-cell lymphoma, ECOG PS Eastern Cooperative Oncology Group performance status, NUT nuclear protein in testis, R/R relapsed/refractory.
  2. aTwo patients, one with advanced BCC and one with NUT midline carcinoma, were enrolled in this cohort before enrollment was stopped due to slow recruitment.
  3. bNineteen patients received trotabresib 45 mg/day 4 days on/24 days off, and four patients received trotabresib 30 mg/day 3 days on/11 days off.
  4. cIncludes salivary gland tumors, colorectal cancer, prostate cancer, lung cancer, astrocytoma other than grade 4, endometrial cancer, thymic cancer, medulloblastoma, and others.
  5. dData presented for one patient.
Back to article page